Rationale for the Use of Cyclophosphamide in COVID 19-Associated Pulmonary Fibrosis

Mikaelyan, K. A.; Tsarenko, S. V.; Petrova, M. V.; Davydova, L. A.; Filimonova, E. V.; Andreev, A. A.; Etnyukov, E. V.

Mikaelyan, K. A.; Tsarenko, S. V.; Petrova, M. V.; Davydova, L. A.; Filimonova, E. V.; Andreev, A. A.; Etnyukov, E. V..

Latin American Journal of Pharmacy ; 41(Special Issue):183-188, 2022.

Article in English | EMBASE | ID: covidwho-1935249

ABSTRACT

ABSTRACT

Pneumonia is a serious complication of the new coronavirus infection, also known as COVID-19. Patients if risk groups who require ICU care and mechanical ventilation are at the highest risk to develop lung fibrosis. This review analyzes the use of cytostatic agents such as cyclophosphamide with his proven efficacy against lung fibrosis of various etiologies and considers its potential effectiveness in the treatment of post-Covid pulmonary fibrosis.

Keywords

adult; article; artificial ventilation; comparative effectiveness; complication; coronavirus disease 2019; drug therapy; high risk population; human; interstitial pneumonia; lung fibrosis; male; pneumonia; cyclophosphamide; cytostatic agent

Search on Google

XML

Collection: Databases of international organizations Database: EMBASE Language: English Journal: Latin American Journal of Pharmacy Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

XML

Collection: Databases of international organizations Database: EMBASE Language: English Journal: Latin American Journal of Pharmacy Year: 2022 Document Type: Article